Transcrip Partners Expands Further with Two New Senior Appointments

Transcrip Partners Expands Further with Two New Senior Appointments


22 November 2010 -- TranScrip Partners LLP, a pharmaceutical development company providing expert advice and hands-on support to pharmaceutical and biotechnology companies across an extensive range of therapeutic areas, today announces the appointment of two new senior partners, Julia Lloyd-Parks and Mark Watling. The move is set to further enhance the organisation's high level expertise in clinical research, clinical development and medical affairs across multiple therapeutic areas. This latest recruitment initiative sees TranScrip expecting to exceed 30 partners, as two more hires are expected this year, with plans afoot for further expansion in 2011.

Julia Lloyd-Parks brings 30 years worth of clinical and drug development expertise to the partnership and is a seasoned expert in anti-infectives, cardiovascular, immunology and transplant therapeutics. She has held clinical research posts in Novartis, Syntex and Innovex. Her responsibilities in these companies covered Phase I to Phase III development programmes, medical information and coordinating international clinical research operations. Julia also worked for Technomark, the industry consulting group, prior to heading up the ant-infectives and immunology project management group at Daiichi Sankyo.

Julia, who gained an M.Sc. in Information Science from City University, London, is an Honorary Fellow of the Institute of Clinical Research.

Mark Watling is a senior pharmaceutical physician with more than 18 years experience in clinical development. Mark served as Medical Director at Cephalon, Head of Medical Partnership at Novo Nordisk and Group Medical Director at Archimedes Pharma, leading teams engaged in the development and approval of CNS, neurology, pain and critical care products. Specific responsibilities included medical support to product commercialisation, through the development of in-house and contracted services that encompassed medical liaison, medical information and pharmacovigilance. He also has CRO experience and was responsible for designing and implementing programmes at both Til Occam and Quintiles.

Commenting on the latest appointments: Dr. Flic Gabbay, the Managing Partner of TranScrip, said: "We are delighted that Julia and Mark have chosen to join our partnership. Their strong clinical development, research and hands on programme management expertise in an array of therapeutic fields, for small, medium sized and large healthcare sector companies, will prove a highly valuable asset to our organisation."

She added: "These appointments mark the commencement of the next phase in TranScrip Partners' development. The partnership has expanded rapidly since its launch in 2008 and we look forward to continuing to bring our substantial and adaptable skill sets to bear on providing bespoke therapeutic support services to our growing base of biotechnology and pharmaceutical clients over the coming years".

About TranScrip Partners TranScrip is a rapidly growing firm of highly respected pharma industry and academic leaders, able to bring creativity towards fast-tracking and de-risking projects, with maturing expansion plans for Europe and the world. Established in October 2008, TranScrip Partners was specifically created to meet the needs of pharmaceutical companies forced to reduce head-counts and consequent access to in-house drug development expertise. TranScrip is structured to fill this gap in the market and can provide pharmaceutical and life science companies with the expertise they require, in a wide range of sub-disciplines and therapeutic areas, on both a short and long term basis, drawn from its extensive company.

Collectively, TranScrip provides knowledge and operational capability in drug development in its widest context, working across multiple therapeutic and ‘functional' areas. Already very substantial by consulting group standards in the pharma space, it offers a flexible model that allows Clients to access Partners' capabilities to fill skill, experience and/or resource gaps, by integrating with and augmenting Client teams.

TranScrip Partners can provide specific individual experts or layered teams of experienced professionals, which can then evolve as required or as Client objectives change. It offers Clients the support of ‘doers' who can think strategically and ‘thinkers' who are happy to get their hands dirty.

Every Client project has leadership and oversight by the most appropriately experienced Partner to ensure "Best in Industry" standards, with built-in continuous professional development for all Partners that interims find hard to afford.


Website: www.transcrip-partners.com

 

For more information contact:

Tristan Jervis De Facto +44 207 861 3019 Email: [email protected]

Paul Branthwaite TranScrip Partners +44 (0) 118 963 7846 E-mail: [email protected]

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.